Results 121 to 130 of about 35,072 (188)

Safety and efficacy of weekly adalimumab 80 mg therapy in pediatric Crohn's disease. [PDF]

J Pediatr Gastroenterol Nutr
Cohen-Sela E, Yerushalmy-Feler A, Rinawi F, Orlanski-Meyer E, Nassar R, Magen-Rimon R, Weintraub Y, Shamir R, Shouval DS, Matar M.   +9 more
europepmc   +1 more source

Psoriasiform adult blaschkitis triggered by adalimumab: a rare paradoxical reaction. [PDF]

An Bras Dermatol
de Almeida HL, Birck MS, Bialecki LMB, Paganelli A, Martini LB, Duquia RP.   +5 more
europepmc   +1 more source

Evaluation of Injection Site Pain and Adherence in Patients Transitioning from a High to Low Volume Adalimumab Formulation (AVT02, Simlandi®) Across Multiple Indications (EASE PAIN). [PDF]

Rheumatol Ther
Shahrokh DK, Vender RB, Lynde CW, Rao J, Afif W, Steinhart AH, Narula N, Sutton E, Thorne C, Bessette L.   +9 more
europepmc   +1 more source

Case Report: Safety and efficacy of combination therapy with adalimumab and anakinra in two patients with severe inflammatory diseases. [PDF]

Front Pediatr
Coslovich S, Bramuzzo M, Pastore S, Chicco D, Lega S, Gortani G, Caiffa T, Tommasini A, Taddio A.   +8 more
europepmc   +1 more source

Efficacy and Safety of Adalimumab as Monotherapy Versus Adalimumab With Methotrexate for Psoriasis: A Systematic Review. [PDF]

Cureus
Alanazi AF, Almahdi MA, Alqurashi SO, Alassaf S, Almohanna A, Alayed ST, Alshehri M, Alsubaie KS, Hakami S.   +8 more
europepmc   +1 more source

Sex Differences in Treatment Expectations, Satisfaction and Tolerance After Switching to CT-P17, an Adalimumab Biosimilar: A Post Hoc Analysis of the YU-MATTER Study. [PDF]

Rheumatol Ther
Gossec L, Bouguen G, Dellal A, Foulley L, Habauzit C, Benkhalifa S, Marotte H.   +6 more
europepmc   +1 more source

Is Routine Monitoring of TNF-α Inhibitor Levels and Antibodies in Pediatric IBD Justified in the Era of Personalized Medicine. [PDF]

J Clin Med
Pytrus T, Szyller HP, Augustynowicz G, Lasocka M, Watras S, Akutko K.   +5 more
europepmc   +1 more source

Model-Based Design of Sustained-Release Formulations of Anti-TNF-α Monoclonal Antibodies for Intravitreal Administration. [PDF]

Pharmaceutics
Reig-López J, Cuquerella-Gilabert M, Zarzoso-Foj J, Mangas-Sanjuán V, Merino V, Merino-Sanjuán M.   +5 more
europepmc   +1 more source

Comparing the pharmacokinetics of adalimumab originator and biosimilar product in patients with Inflammatory bowel disease or autoimmune disease. [PDF]

Saudi Pharm J
Drweesh H, Alotaibi A, Alqassim HA, Eid MM, Emsaad SA, Saad MO, Higazy AS, Alturaiki A, Almutairi F, Alhussain A, Assiri A, Alkofide H, Alruthia Y, Albassam A, Alsultan A.   +14 more
europepmc   +1 more source